


Company	AbbVie		Date	08/06/21	
Prepared by	Iaing		Data taken from	BI Stock Data	
Where traded	NYS	Industry	Drug Manufacturers - General		
Capitalization --- Outstanding Amounts	Reference				
Preferred (\$M)	0.0	% Insiders	% Institution		
Common (M Shares)	1,776.0	0.1	63.0		
Debt (\$M)	82,138.0	% to Tot Cap	86.7	% Pot Dil	0.4

Stock Selection Guide

Symbol: ABBV

1 VISUAL ANALYSIS of Sales, Earnings, and Price



FY 2021 Q2	Sales (\$M)	Earnings Per Share
Latest Quarter	13,959	0.42
Year Ago Quarter	10,425	-0.46
Percentage Change	33.9%	191.3%

- | | | | |
|-----------------------------------|-------|--|------|
| (1) Historical Sales Growth | 10.7% | (3) Historical Earnings Per Share Growth | 6.5% |
| (2) Estimated Future Sales Growth | 8.0% | (4) Estimated Future Earnings Per Share Growth | 8.0% |

2 EVALUATING Management

AbbVie

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Last 5 Year Avg.
Pre-tax Profit on Sales	21.0%	31.1%	28.4%	11.9%	29.1%	30.8%	27.4%	15.9%	25.3%	7.4%	21.4%
% Earned on Equity		157.4%	113.6%	37.7%	103.6%	89.4%	78.6%	-185.3%	-94.9%	31.4%	-16.2%
% Debt To Capital	0.0%	82.3%	76.6%	89.6%	88.9%	88.8%	88.0%	126.5%	114.0%	86.8%	100.8%

3 PRICE-EARNINGS HISTORY as an indicator of the future

This shows how stock prices have fluctuated with earnings and dividends. It is building block for translating earnings into future stock prices.

CLOSING PRICE 114.45 (08/06/21)

HIGH THIS YEAR 119.15

LOW THIS YEAR 79.11

	A	B	C	D	E	F	G	H
Year	Price		Earnings	Price Earnings Ratio		Dividend	% Payout	% High Yield
	High	Low	Per Share	High A / C	Low B / C	Per Share	F / C * 100	F / B * 100
2016	68.1	50.7	3.63	18.8	14.0	2.28	62.8	4.5
2017	99.1	59.3	3.30	30.0	18.0	2.56	77.6	4.3
2018	125.9	77.7	3.66	34.4	21.2	3.59	98.1	4.6
2019	92.3	62.7	5.28	17.5	11.9	4.28	81.1	6.8
2020	109.2	62.6	2.72	40.1	23.0	4.72	173.5	7.5
AVERAGE		62.6		28.2	17.6		98.6	
CURRENT/TTM			3.71			5.20	140.2	
AVERAGE PRICE EARNINGS RATIO: 22.9				CURRENT PRICE EARNINGS RATIO: 30.8				

4 EVALUATING RISK and REWARD over the next 5 years

Assuming one recession and one business boom every 5 years, calculations are made of how high and how low the stock might sell. The upside-downside ratio is the key to evaluating risk and reward.

A HIGH PRICE - NEXT 5 YEARS

Avg. High P/E 30.0 X Estimate High Earnings/Share 5.45 = Forecasted High Price \$ 163.5

B LOW PRICE - NEXT 5 YEARS

(a) Avg. Low P/E 20.0 X Estimate Low Earnings/Share 3.71 = Forecasted Low Price \$ 74.2

(b) Avg. Low Price of Last 5 Years 62.6

(c) Recent Market Low Price 62.6

(d) Price Dividend Will Support $\frac{\text{Indicated Dividend}}{\text{High Yield}} = \frac{5.20}{7.55\%} = 68.9$

Selected Forecasted Low Price \$ 74.2

C ZONING using 25%-50%-25%

Forecasted High Price 163.5 Minus Forecasted Low Price 74.2 = 89.3 Range. 25% of Range 22.3

Buy Zone 74.2 to 96.5

Hold Zone 96.5 to 141.2

Sell Zone 141.2 to 163.5

Present Market Price of 114.45 is in the **HOLD** Zone

D UPSIDE DOWNSIDE RATIO (POTENTIAL GAIN VS. RISK OR LOSS)

$\frac{\text{High Price} - \text{Present Price}}{\text{Present Price} - \text{Low Price}} = \frac{163.5 - 114.45}{114.45 - 74.2} = \frac{49.09}{40.25} = 1.2$ To 1

E PRICE TARGET (Note: This shows the potential market price appreciation over the next five years in simple interest terms.)

$\frac{\text{High Price} - \text{Closing Price}}{\text{Closing Price}} = \frac{163.5 - 114.45}{114.45} = 1.4289$ X 100 = 142.89 - 100 = 42.9 % Appreciation

5 5-YEAR POTENTIAL

This combines price appreciation with dividend yield to get an estimate of total return. It provides a standard for comparing income and growth stocks.

A $\frac{\text{Indicated Annual Dividend}}{\text{Closing Price}} = \frac{4.72}{114.45} = 0.0454 = 4.5\%$ Current Yield

B AVERAGE YIELD - USING FORECAST HIGH P/E

$\frac{\text{Avg. \% Payout}}{\text{Forecast High PE}} = \frac{98.6\%}{30.00} = 3.3\%$

AVERAGE YIELD - USING FORECAST AVERAGE P/E

$\frac{\text{Avg. \% Payout}}{\text{Forecast Average PE}} = \frac{98.6\%}{25.00} = 3.9\%$

C COMPOUND ANNUAL RETURN - USING FORECAST HIGH P/E

Annualized Appreciation 7.4 %
Average Yield 3.3 %
Annualized Rate of Return 10.7 %

COMPOUND ANNUAL RETURN - USING FORECAST AVG P/E


Annualized Appreciation 3.6 %
Average Yield 3.9 %
Annualized Rate of Return 7.5 %

Notes: ABBV 8/8/21

Date	Subject	Description	Type
08/03/21	ABBV data Value Line	I changed data to Value Line when updating my SSG on Aug 3 2021.	Community
07/17/21	Delisting of Cannabis?	How much will this affect Abbvie, will they be able to take advantage? Is a hot issue now.	Community
07/14/21	Completing an accurate SSG	BI's SSG model makes 5-year steady growth projections. ABBV has benefited from highly profitable Humira drug. It's patent runs out in 2023, with an expected price drop afterwards. This will be mitigated by good sales in Imbruvica, Skyrizi, and Rinvoq and Allergan (botox) drugs. This creates a lot of uncertainty about profits beyond 2023. Analysts' estimated losses drive the EPS growth into negative figures. This reduces 5-year estimated compounded annual returns to 8 and 2%	Community
07/14/21	Potential price drop in 2023	Drug Humira goes off-patent in 2023. Competition will cut into its sales and profits will drop. I would keep the company until 2022-23 and possibly sell it then at the end of the patent. Purchase of Allergan may offset this anticipated drop, but I would have to research Allergan.	Community
04/01/21	low price estimate	Low estimate done manually using 23% off current price. The stock is in the hold range and I agree.	Community
01/03/21	ABBV : method of choosing forecasted low price	75% off the current price was used to calculate the forecasted low price.	Community
08/22/20	Long Term Debt 2020 Qtrs.	It appears Morningstar is NOT passing through the Long Term Debt Non Current which makes the Debt line drop. The Value Line and 2nd Qtr 10 Q has the values at of 82? billion. 1st quarter was correct a 67 Billion. Not sure why the M* did not get it correctly for the 2nd Qtr. I wonder if this increase and mixed balance sheet is due to the acquisition of Allergan. On May 8, 2020, AbbVie completed its previously announced acquisition of all outstanding equity interests in Allergan in a cash and stock transaction.	Community
06/29/20	Debt	Wow! Debt is very high!	Community
08/11/19	2018 earnings adjustment	From the 10k Stemcentrx-related impairment charge of \$4.1 billion This is a one-time charge so adding that back in to revenue: Sales = 32753 + 4100 = 36853 Ptp = 5197 + 4100 = 9297 NI = 5657 + 4100 = 9757 Earnings = 9757 / 1546 = 6.31	Community

Quarterly Growth Trend Data

Graph: Trailing 4 Quarters, Last 5 Years of Data



Period	Quarterly Data								Last 12 Months Data								
	EPS		Pre-Tax Profit			Sales		Income Tax Rate	EPS	Pre-Tax Profit		Sales	Income Tax		%Change		
	\$	%Change	\$ Mil	%Sales	%Change	\$ Mil	%Change		\$	\$ Mil	%Sales		\$ Mil	%Rate	EPS	Pre-Tax Profit	Sales
06/21	0.42	191.3	1,163.0	8.3	267.8	13,959.0	33.9	33.9	3.71	6,023.0	11.2	53,729.0	2,288.0	38.0	-21.1	-19.5	48.3
03/21	1.99	-1.5	3,867.0	29.7	24.8	13,010.0	50.9	8.1	2.83	4,167.0	8.3	50,195.0	1,160.8	27.9	-49.9	-53.6	47.4
12/20	0.01	-99.5	-1,507.0	-10.9	-149.0	13,858.0	59.2	102.5	2.86	3,398.0	7.4	45,804.0	902.2	26.6	-45.8	-59.7	37.7
09/20	1.29	2.4	2,500.0	19.4	24.9	12,902.0	52.2	7.5	4.73	7,979.0	19.6	40,650.0	250.5	3.1	118.5	167.8	23.7
06/20	-0.46	-193.9	-693.0	-6.6	-185.9	10,425.0	26.3	-6.6	4.70	7,480.0	20.6	36,227.0	204.4	2.7	73.1	100.1	11.0
03/20	2.02	22.4	3,098.0	35.9	21.8	8,619.0	10.1	2.8	5.65	8,980.0	26.4	34,057.0	578.1	6.4	62.1	81.6	4.3
12/19	1.88	252.2	3,074.0	35.3	229.5	8,704.0	4.8	8.9	5.28	8,426.0	25.3	33,266.0	555.5	6.6	47.7	62.1	1.6
09/19	1.26	-30.4	2,001.0	23.6	-27.5	8,479.0	3.0	5.9	2.17	2,979.0	9.1	32,867.0	301.9	10.1	-55.3	-66.0	2.1
06/19	0.49	-61.1	807.0	9.8	-59.9	8,255.0	-0.3	8.2	2.72	3,739.0	11.5	32,624.0	329.0	8.8	-32.8	-53.8	5.4
03/19	1.65	-5.2	2,544.0	32.5	-9.0	7,828.0	-1.3	3.5	3.49	4,944.0	15.1	32,647.0	351.8	7.1	-12.2	-41.4	10.2

Quarterly Growth Trend Data

Graph: Trailing 4 Quarters, Last 5 Years of Data

Quarterly Data									Last 12 Months Data								
Period	EPS		Pre-Tax Profit			Sales		Income Tax Rate	EPS	Pre-Tax Profit		Sales	Income Tax		%Change		
	\$	%Change	\$ Mil	%Sales	%Change	\$ Mil	%Change			\$	\$ Mil		%Sales	\$ Mil	%Rate	EPS	Pre-Tax Profit
12/18	-1.24	-4,216.7	-2,373.0	-28.6	-298.9	8,305.0	7.3	23.1	3.58	5,197.0	15.9	32,753.0	331.3	6.4	8.7	-32.7	16.1
09/18	1.81	79.2	2,761.0	33.5	31.8	8,236.0	17.7	0.5	4.84	8,763.0	27.2	32,187.0	2,148.9	24.5	17.8	2.7	18.0
06/18	1.26	5.9	2,012.0	24.3	-14.5	8,278.0	19.2	1.4	4.04	8,097.0	26.2	30,946.0	2,423.6	29.9	-0.7	-4.2	15.9
03/18	1.74	64.2	2,797.0	35.3	34.1	7,934.0	21.4	0.5	3.97	8,438.0	28.5	29,612.0	2,887.9	34.2	2.8	3.0	12.9
12/17	0.03	-96.5	1,193.0	15.4	-40.3	7,739.0	13.9	95.6	3.29	7,727.0	27.4	28,216.0	2,982.2	38.6	-9.4	-2.0	10.1
09/17	1.01	4.1	2,095.0	29.9	4.0	6,995.0	8.8	22.2	4.11	8,532.0	31.3	27,273.0	1,900.9	22.3	11.1	9.2	8.0
06/17	1.19	21.4	2,353.0	33.9	12.3	6,944.0	7.6	18.6	4.07	8,451.0	31.6	26,710.0	1,851.4	21.9	17.3	13.5	7.9
03/17	1.06	27.7	2,086.0	31.9	17.5	6,538.0	9.7	18.0	3.86	8,194.0	31.3	26,218.0	1,888.9	23.1	16.3	16.6	10.3
12/16	0.85	-7.6	1,998.0	29.4	3.8	6,796.0	6.2	30.4	3.63	7,884.0	30.8	25,638.0	1,931.4	24.5	16.3	18.6	12.2
09/16	0.97	31.1	2,014.0	31.3	22.3	6,432.0	8.2	20.7	3.70	7,810.0	30.9	25,242.0	1,733.0	22.2	118.9	112.0	15.2
06/16	0.98	18.1	2,096.0	32.5	24.9	6,452.0	17.8	23.2	3.47	7,443.0	30.1	24,754.0	1,728.1	23.2	175.4	173.2	18.0
03/16	0.83	31.7	1,776.0	29.8	27.2	5,958.0	18.2	23.8	3.32	7,025.0	29.5	23,777.0	1,550.2	22.1	199.1	183.4	16.3
12/15	0.92	280.4	1,924.0	30.1	285.5	6,400.0	17.4	21.2	3.12	6,645.0	29.1	22,859.0	1,516.7	22.8	186.2	180.5	14.5
09/15	0.74	138.7	1,647.0	27.7	139.7	5,944.0	18.4	24.8	1.69	3,684.0	16.8	21,911.0	847.7	23.0	-26.5	-24.0	11.7
06/15	0.83	22.1	1,678.0	30.6	17.1	5,475.0	11.1	18.6	1.26	2,724.0	13.0	20,986.0	637.6	23.4	-51.4	-50.0	9.0
03/15	0.63	3.3	1,396.0	27.7	8.6	5,040.0	10.5	26.8	1.11	2,479.0	12.1	20,437.0	609.9	24.6	-56.8	-53.9	7.4
12/14	-0.51	-172.9	-1,037.0	-19.0	-172.1	5,452.0	6.7	21.9	1.09	2,369.0	11.9	19,960.0	565.1	23.9	-57.4	-55.6	6.2
09/14	0.31	-48.3	687.0	13.7	-46.6	5,019.0	7.8	26.4	2.30	4,845.0	24.7	19,619.0	1,152.3	23.8	-18.8	-13.6	3.9
06/14	0.68	3.0	1,433.0	29.1	4.8	4,926.0	5.0	23.4	2.59	5,444.0	28.3	19,258.0	1,276.9	23.5	-20.0	-8.1	2.8
03/14	0.61	1.7	1,286.0	28.2	3.8	4,563.0	5.4	23.8	2.57	5,379.0	28.3	19,024.0	1,242.1	23.1	-23.9	-9.7	2.6
12/13	0.70	-28.1	1,439.0	28.2	-16.0	5,111.0	-1.8	21.6	2.56	5,332.0	28.4	18,790.0	1,205.7	22.6	-23.3	-6.9	2.2
09/13	0.60	-40.2	1,286.0	27.6	-19.8	4,658.0	3.3	25.0	2.83	5,605.9	29.7	18,884.8	1,106.6	19.7	-8.5	4.4	4.7
06/13	0.66	-17.7	1,368.0	29.2	-2.4	4,692.0	4.4	21.9	3.24	5,923.9	31.6	18,734.8	816.0	13.8	54.0	54.4	4.4
03/13	0.60	7.3	1,239.0	28.6	23.2	4,329.0	3.7	21.9	3.38	5,957.9	32.1	18,535.8	637.5	10.7	48.5	56.1	4.6
12/12	0.97	32.9	1,712.9	32.9	26.1	5,205.8	7.0	10.1	3.34	5,724.7	31.1	18,379.7	473.9	8.3	53.5	56.0	5.4
09/12	1.00	12,437.5	1,604.0	35.6	2,141.1	4,508.0	2.3	1.2	3.10	5,369.7	29.8	18,038.0	506.6	9.4			
06/12	0.80	-17.7	1,402.0	31.2	1.5	4,493.0	5.1	9.6	2.10	3,837.3	21.4	17,938.7	1,144.8	29.8			
03/12	0.56	22.1	1,005.8	24.1	17.2	4,172.9	7.1	12.2	2.28	3,816.0	21.5	17,720.1	936.4	24.5			
12/11	0.73		1,357.9	27.9		4,864.1		14.8									
09/11	0.01		71.6	1.6		4,408.7		82.8									
06/11	0.98		1,380.7	32.3		4,274.4		-11.5									
03/11	0.46		858.3	22.0		3,896.8		15.7									